vos badges Fourchette 52 semaines $1–$3 89% of range Note des analystes BUY 14 analysts Objectif de cours $2 P/E -6.2 ROE -929.3% Marge nette -82.5%

PACB Aperçu de l'action Prix, capitalisation boursière, P/E, EPS, ROE, dette/capitaux propres, fourchette sur 52 semaines

03
Prix $2.54
Capitalisation Boursière (MRQ) $789M
P/E (TTM) -6.2
BPA (TTM) $-0.41
Revenu (TTM) $159M
ROE (TTM) -929.3%
Fourchette 52 semaines $1–$3

PACB Graphique du cours de l'action OHLCV quotidien avec indicateurs techniques — panoramique, zoom et personnalisez votre vue

04
fourchette
barres

La granularité des barres s'adapte à la période sélectionnée — survolez le graphique pour voir l'ouverture/le maximum/le minimum/la clôture d'une barre.

À propos de Pacific Biosciences of California, Inc. - Common Stock Présentation de l'entreprise depuis Wikipedia

05 · wikidata

Pacific Biosciences of California, Inc. (a.k.a. PacBio) is an American biotechnology company founded in 2004 that develops and manufactures systems for gene sequencing and some novel real time biological observation. PacBio has two principal sequencing platforms: single-molecule real-time sequencing (SMRT), based on the properties of zero-mode waveguides and sequencing by binding (SBB) chemistry, which uses native nucleotides and scarless incorporation for DNA binding and extension.

History

The company was founded based on research done at Cornell University that combined semiconductor processing and photonics with biotechnology research. Three graduate students in the lab of Professors Watt W. Webb — Jonas Korlach — and Harold Craighead — Steve Turner and Mathieu Foquet — became the first employees.

It began under the name Nanofluidics, Inc. The company raised nearly US$400,000,000 in six rounds of primarily venture capital financing, making it one of the most capitalized startups in 2010 leading up to their public offering in October of that year. Key investors included Mohr Davidow Ventures, Kleiner, Perkins, Caufield & Byers, Alloy Ventures, and Wellcome Trust.

The company's first commercial product, the PacBio RS, was sold to a limited set of customers in 2010 and was commercially released in early 2011. A subsequent version of the sequencer called the PacBio RS II was released in April 2013.

Leadership

In 2004, Kleiner Perkins entrepreneur-in-residence Hugh Martin became CEO. On 6 January 2012 board member Michael Hunkapiller, PhD assumed the role of CEO. Hunkapiller retired in September 2020, and was replaced by chairman of the board Christian Henry. Henry was a former executive VP and chief commercial officer of Illumina before joining the board at PacBio in July 2018.

Illumina: attempted acquisition

On 1 November 2018, Illumina, Inc. agreed to purchase PacBio for US$1.2 billion in cash. The deal was expected to close in the fourth quarter of 2019. In December 2019, the Federal Trade Commission sued to block the acquisition. The deal was abandoned with an announcement on 2 January 2020. Illumina further agreed to pay Pacific Biosciences a $98 million US termination fee plus previously agreed upon deal extension payments of $22 million US in February and $6 million US in March 2020.

Sequencing technology

Sequencing instruments

The company's first scientific instrument, called the PacBio RS, was released to a limited set of customers in late 2010., with full commercial release in early 2011. Sequencing provider GATC Biotech was selected by Pacific Biosciences as its first European service provider in late 2010. A new version of the sequencer was released in April 2013 it produced longer sequence reads and higher throughput than the original RS instrument. The RS instrument will officially be supported until the end of 2021. In September 2015, the company released a new sequencing instrument, the Sequel System, with increased sequencing capacity at a smaller size and lower price compared to the PacBio RS II. Subsequently, in October 2022, PacBio launched a new sequencing system, which can sequence 1,300 human genomes per year as compared to 86 per year of the previous PacBio sequencing machines.

Reagents and SMRT Cells

To use either instrument, customers must also purchase reagent packs for DNA preparation and sequencing and small consumables called "SMRT Cells." Cells for early forms of the sequencer are slightly less than one-centimeter square and contains tens of thousands of zero-mode waveguides, whereas newer systems have a higher density of cells and contain 25 million zero-mode waveguides (ZMWGs), allowing for faster DNA sequencing.

Software and applications

Their secondary analysis bioinformatics product for the RS, called “SMRT Analysis”, was open source. For the Sequel system the secondary analysis software was reorganized as the "SMRT Link" application. In 2013, the company released new bioinformatics tools for automated genome assembly (HGAP) and finishing (Quiver).

Source : Wikipedia (Anglais), CC BY-SA 4.0 · Voir sur Wikipedia ↗

Wikidata ↗

secteurHealthcare industrieLife Sciences Tools & Services employés485 paysUS

Performance sur 10 ans Tendances du chiffre d'affaires, du bénéfice net, des marges et du BPA

06
Revenu$160M
2016-12-31 → 2025-12-31
BPA$-1.82
2018-12-31 → 2025-12-31
Flux de trésorerie libre$-114M
2016-12-31 → 2025-12-31
Marge nette-82.5%
2016-12-31 → 2025-12-31
Valorisation et Ratios 07–12

Valorisation Ratios P/E, P/S, P/B, EV/EBITDA — l'action est-elle chère ou bon marché ?

Métrique Tendance sur 5 ans PACB moyenne 5 ans Médiane des pairs Verdict
P/E (TTM) -6.2moyenne 5 ans ≈-7.8 ≈-7.8 · ·
P/S (TTM) 5.0moyenne 5 ans ≈13.8 ≈13.8 4.6 Sous-évalué
P/B (MRQ) -23.8moyenne 5 ans ≈23.9 ≈23.9 · ·
Cours / FCF (TTM) -6.4moyenne 5 ans ≈-12.5 ≈-12.5 · ·
Cours / Flux de trésorerie (TTM) -6.7moyenne 5 ans ≈-13.1 ≈-13.1 · ·
Cours / Actif net tangible (MRQ) -17.1 · · ·

La médiane des pairs est calculée sur une base standardisée par métrique et peut ne pas toujours correspondre à la base TTM/MRQ indiquée pour cette action.

valeur · ≈ moyenne 5 ans · médiane du secteur · verdict par rapport à la médiane

Historique des bénéfices BPA réel vs estimation, surprise %, taux de succès, prochaine date de publication des résultats

14
Surprise Moyenne -97.7%
Prochain rapport Nov 03, 2026
PériodeRapportEPS ActualBPA est.Surprise
30 juin 2026 Aoû 3, 2026 $-0.14 $-0.13 -7.9%
31 mars 2026 $-0.12 $-0.14 12.7%
31 décembre 2025 $-0.12 $-0.15 20.3%
30 septembre 2025 $-0.13 $-0.15 16.1%
30 juin 2025 $-0.14 $-0.17 19.3%
31 mars 2025 $-1.44 $-0.19 -646.9%

Fondamentaux complets Tous les indicateurs par an — compte de résultat, bilan, flux de trésorerie

15
Compte de résultat 17
Métrique Tendance 202520242023202220212020201920182017201620152014
Revenue $160M$154M$201M$128M$131M$79M$91M$79M$93M$91M$93M$61M
Cost of Revenue $114M$117M$148M$79M$72M$46M$56M$54M$59M$47M$39M$37M
Gross Profit $46M$37M$53M$49M$59M$33M$35M$25M$35M$44M$53M$23M
R&D Expense $97M$135M$187M$193M$113M$64M$60M$63M$65M$68M$60M$48M
SG&A Expense $141M$175M$170M$161M$124M$73M$75M$63M$59M$48M$45M$38M
Operating Expenses $600M$512M$387M$356M$269M$137M$135M$126M$124M$115M$83M$86M
Operating Income $-554M$-474M$-334M$-307M$-210M$-104M$-101M$-101M$-90M$-71M$-29M$-63M
Interest Expense ··$14M$15M$13M$267.0K$3M$2M$3M$3M$3M$3M
Other Non-op $15M$24M$33M$8M$93.0K$2M$1M$848.0K$516.0K$103.0K$364.0K$-478.0K
Pretax Income $-546M$-310M$-318M$-314M$-275M$29M$-84M·····
Income Tax $318.0K$316.0K$-11M$0$-94M·······
Net Income $-546M$-310M$-307M$-314M$-181M$29M$-84M$-103M$-92M$-74M$-32M$-66M
EPS (Basic) $-1.82$-1.13$-1.21$-1.40$-0.89$0.18$-0.55$-0.76····
EPS (Diluted) $-1.82$-1.59$-1.21$-1.40$-0.89$0.17$-0.55$-0.76····
Shares (Basic) 299,959,000274,488,000253,629,000224,550,000204,136,000165,187,000152,527,000135,094,000····
Shares (Diluted) 299,959,000288,366,000253,629,000224,550,000204,136,000174,970,000152,527,000135,094,000····
EBITDA $-554M$-474M$-334M$-307M$-210M$-104M$-101M$-94M$-81M$-67M$-25M$-59M
Bilan 30
Métrique Tendance 202520242023202220212020201920182017201620152014
Cash & Equivalents $64M$55M$180M$325M$461M$82M$30M$19M$17M$17M$34M$36M
Short-term Investments $216M$335M$452M$447M$584M$237M$19M$84M$46M$55M$49M$65M
Receivables $35M$28M$37M$19M$24M$17M$15M$9M$13M$11M$5M$3M
Inventory $49M$59M$57M$50M$25M$14M$13M$18M$23M$16M$11M$11M
Prepaid Expense $11M$19M$17M$10M$7M$5M$3M$3M$2M$10M$12M$2M
Other Current Assets ········$931.0K$476.0K$741.0K$107.0K
Current Assets $375M$496M$742M$852M$1.10B$356M$81M$132M$102M$109M$111M$118M
PP&E (Net) $24M$31M$36M$42M$33M$25M$30M$34M$38M$15M$9M$7M
PP&E (Gross) $117M$112M$111M$107M$89M$75M$74M$71M$70M$52M$42M$37M
Accum. Depreciation $92M$82M$75M$65M$56M$50M$44M$37M$32M$37M$34M$30M
Goodwill $318M$318M$462M$410M$410M·······
Intangibles $15M$390M$457M$410M$411M·······
Other Non-current Assets $9M$9M$13M$11M$1M$43.0K$42.0K$43.0K$45.0K$10M$8M$29.0K
Total Assets $784M$1.26B$1.75B$1.77B$2.01B$414M$148M$170M$144M$138M$131M$124M
Accounts Payable $21M$17M$15M$12M$11M$4M$8M$7M$9M$8M$5M$6M
Accrued Liabilities $34M$23M$46M$33M$36M$17M$13M$13M$13M$17M$16M$11M
Short-term Debt ·$0$490.0K$2M$2M·$16M·····
Current Liabilities $73M$66M$95M$263M$72M$39M$49M$27M$29M$34M$38M$31M
Capital Leases $57M$15M$32M$41M$50M$38M$42M····$2M
Other Non-current Liabilities $0$546.0K$751.0K$1M$3M$752.0K···$2M$1M$2M
Total Liabilities $779M$754M$1.04B$1.20B$1.22B$78M$93M$56M$58M$53M$58M$69M
Long-term Debt ···$897M$896M·$16M$15M$14M$16M·$14M
Total Debt ·$0$490.0K$2M$2M·$16M·····
Common Stock $302.0K$294.0K$268.0K$227.0K$221.0K$192.0K$153.0K$150.0K$116.0K$93.0K$80.0K$74.0K
Paid-in Capital $2.70B$2.65B$2.54B$2.10B$2.01B$1.37B$1.12B$1.10B$966M$872M$787M$736M
Retained Earnings $-2.70B$-2.15B$-1.84B$-1.53B$-1.22B$-1.04B$-1.07B$-982M$-880M$-788M$-713M$-681M
AOCI $457.0K$422.0K$219.0K$-5M$-1M$85.0K$5.0K$-36.0K$-32.0K$5.0K$-7.0K$9.0K
Stockholders' Equity $5M$507M$701M$563M$791M$335M$55M$114M$86M$85M$74M$55M
Liabilities + Equity $784M$1.26B$1.75B$1.77B$2.01B$414M$148M$170M$144M$138M$131M$124M
Shares Outstanding 301,956,000294,418,000267,744,000226,505,000220,978,000192,294,000153,119,000150,244,000116,277,00092,677,00079,983,00073,927,000
Flux de trésorerie 16
Métrique Tendance 202520242023202220212020201920182017201620152014
D&A ·······$7M$8M$4M$4M$4M
Stock-based Comp $42M$71M$72M$79M$73M$18M$16M$23M$20M$20M$14M$10M
Deferred Tax $-546.0K$-205.0K$-11M$0$-94M·······
Amort. of Intangibles $369M$27M$8M$913.0K$0$0$0·····
Restructuring ·$13M··········
Other Non-cash ·······$6M$-4M$-17M$-34M$528.0K
Operating Cash Flow $-111M$-206M$-259M$-263M$-111M$20M$-78M$-66M$-68M$-68M$-48M$-51M
CapEx $3M$6M$9M$17M$6M$1M$3M$2M$10M$8M$3M$2M
Investing Cash Flow $115M$124M$5M$116M$-679M$-219M$62M$-38M$-2M$-15M··
Stock Issued $0$0$189M$0$32M$46M$9M$10M$9M$8M$7M$4M
Net Stock Activity $0$0$15M$11M$32M$46M$9M$10M$9M$8M$7M$4M
Financing Cash Flow $3M$-43M$109M$10M$1.17B$252M$27M$107M$69M$66M··
Net Change in Cash $8M$-125M$-146M$-138M$380M···$-258.0K$-17M$-3M$10M
Taxes Paid $481.0K$256.0K$140.0K·········
Free Cash Flow $-114M$-212M$-268M$-280M$-117M$18M$-81M$-68M$-78M$-76M$-51M$-53M
Levered FCF ··$-282M·$-125M·······
Rentabilité 8
Métrique Tendance 202520242023202220212020201920182017201620152014
Gross Margin 28.6%24.2%26.3%38.2%45.1%41.3%38.0%31.9%37.1%48.7%57.6%38.6%
Operating Margin -346.1%-308.0%-166.8%-239.4%-161.2%-132.3%-110.6%-128.4%-96.1%-78.5%-31.4%-103.7%
Net Margin -341.5%-201.2%-153.0%-244.9%-138.8%37.3%-92.6%-130.4%-98.6%-82.0%-34.2%-109.2%
Pretax Margin -341.3%-201.0%-158.7%-244.9%-210.6%·······
EBITDA Margin -346.1%-308.0%-166.8%-239.4%-161.2%-132.3%-110.6%-119.3%-87.0%-74.3%-27.4%-96.8%
ROA -53.4%-20.6%-17.5%-16.7%-15.0%10.5%-52.9%-65.2%-65.4%-55.3%-24.8%-50.7%
ROE -1634.9%-64.6%-41.9%-52.8%-22.2%12.7%-158.8%-83.4%-108.0%-94.0%-49.3%-106.6%
ROIC -10360.5%-93.7%-46.0%·-17.5%·······
Liquidité et Solvabilité 4
Métrique Tendance 202520242023202220212020201920182017201620152014
Current Ratio 5.17.57.83.215.49.21.64.93.53.22.93.7
Quick Ratio 4.36.37.03.014.98.71.34.12.72.52.33.3
Debt / Equity ·0.00.00.00.0·0.3·····
Interest Coverage ··-23.3-20.9-16.8-391.0-38.5-41.7-30.7-22.0-10.0-22.2
Efficacité 3
Métrique Tendance 202520242023202220212020201920182017201620152014
Asset Turnover 0.20.10.10.10.10.30.60.50.70.70.70.5
Inventory Turnover 2.12.02.82.13.73.43.62.63.03.53.53.5
Receivables Turnover 5.14.87.26.06.44.97.67.17.510.921.419.7
Par action 6
Métrique Tendance 202520242023202220212020201920182017201620152014
Book Value / Share $0.02$1.72$2.62$2.49$3.58$1.74$0.36$0.76$0.74$0.91$0.92$0.74
Revenue / Share $0.53$0.53$0.79$0.57$0.64$0.45······
Cash Flow / Share $-0.37$-0.71$-1.02$-1.17$-0.54$0.11······
Cash / Share $0.21$0.19$0.67$1.44$2.08$0.42$0.19$0.13$0.14$0.18$0.42$0.49
Dividend / Share $0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00
EPS (TTM) $-1.82$-1.59$-1.21$-1.40$-0.89$0.17$-0.55$-0.76····
Taux de croissance 3
Métrique Tendance 202520242023202220212020201920182017201620152014
Revenue YoY 3.9%-23.2%56.3%-1.7%65.4%·······
Revenue CAGR 3Y 7.6%5.7%36.5%·········
Revenue CAGR 5Y 15.2%···········
Valorisation (TTM) 14
Métrique Tendance 202520242023202220212020201920182017201620152014
Revenue TTM $160M$154M$201M$128M$131M$79M$91M$79M$93M$91M$93M$61M
Net Income TTM $-546M$-310M$-307M$-314M$-181M$29M$-84M$-103M$-92M$-74M$-32M$-66M
Market Cap $565M$539M$2.63B$1.85B$4.52B$4.99B$787M$1.11B$307M$352M$1.05B$580M
Enterprise Value ·$149M$2.00B$1.08B$3.48B·$754M·····
P/E -1.0-1.2-8.1-5.8-23.0152.6-9.3-9.7····
P/S 3.53.513.114.434.663.28.714.13.33.911.39.6
P/B 105.61.13.73.35.714.914.39.73.64.214.310.5
P / Tangible Book ·····14.9······
P / Cash Flow -5.1-2.6-10.1-7.0-40.7255.8-10.0-16.7-4.5-5.2-21.9-11.3
P / FCF -5.0-2.5-9.8-6.6-38.6270.2-9.7-16.3-3.9-4.6-20.6-10.9
EV / EBITDA ·-0.3-6.0-3.5-16.5·-7.5·····
EV / FCF ·-0.7-7.4-3.9-29.7·-9.3·····
EV / Revenue ·1.010.08.426.7·8.3·····
Earnings Yield -97.3%-86.9%-12.3%-17.1%-4.3%0.66%-10.7%-10.3%····

Période la plus récente à gauche · valeurs nulles affichées comme ·

États financiers Compte de résultat, bilan, flux de trésorerie — annuel, sur les 5 dernières années

16
Métrique 2025-12-312024-12-312023-12-312022-12-312021-12-31
Revenu $160M $154M $201M $128M $131M
Marge Brute % 28.6% 24.2% 26.3% 38.2% 45.1%
Marge d'exploitation % -346.1% -308.0% -166.8% -239.4% -161.2%
Résultat net $-546M $-310M $-307M $-314M $-181M
BPA dilué $-1.82 $-1.59 $-1.21 $-1.40 $-0.89

Détenteurs institutionnels (13F) 244 déclarants · $360.0M total · Au 30 juin 2026

17

Institutions qui déclarent détenir cette action dans leur Formulaire SEC 13F trimestriel. Uniquement les positions longues ; un même déclarant peut apparaître deux fois pour des jambes d'options distinctes. Les jambes put/call compensatoires importantes reflètent généralement la tenue de marché ou un inventaire couvert, pas une conviction directionnelle.

Détenteurs 244
Valeur détenue $360.0M
Nouvelles positions 24
Positions clôturées 28
Activité institutionnelle — Q2 2026 vs trimestre précédent
Nouvelles positions Positions clôturées Augmenté Diminué Variation nette des actions
24 (-30 vs T. préc.) 28 (-2 vs T. préc.) 72 (+14 vs T. préc.) 80 (+4 vs T. préc.) +4.3M

Comparé à Q1 2026. Les dépôts de formulaire 13F de la SEC sont dus dans les 45 jours suivant la fin du trimestre, plus une courte période tampon pour les déposants tardifs — les trimestres encore dans cette fenêtre sont ignorés au profit de la paire la plus récente entièrement déclarée.

Institution Valeur Actions % de 13F suivies Type
BlackRock, Inc. $54 330 444 32 339 550 15,09% Actions
ARK Investment Management LLC $50 032 778 29 781 416 13,90% Actions
SOFTBANK GROUP CORP. $34 358 638 20 451 570 9,54% Actions
VANGUARD GROUP INC $31 859 776 17 037 314 8,85% Actions
VANGUARD CAPITAL MANAGEMENT LLC $22 508 529 13 397 934 6,25% Actions
GEODE CAPITAL MANAGEMENT, LLC $12 782 429 7 606 518 3,55% Actions
Sumitomo Mitsui Trust Group, Inc. $10 096 321 6 009 715 2,80% Actions
Amova Asset Management Americas, Inc. $10 036 224 6 009 715 2,79% Actions
STATE STREET CORP $10 014 774 5 961 175 2,78% Actions
Point72 Asset Management, L.P. $8 042 664 4 787 300 2,23% Actions
TWO SIGMA INVESTMENTS, LP $7 127 566 4 242 599 1,98% Actions
D. E. Shaw & Co., Inc. $7 069 686 4 208 146 1,96% Actions
MILLENNIUM MANAGEMENT LLC $6 656 903 3 962 442 1,85% Actions
Point72 (DIFC) Ltd $5 465 775 4 270 137 1,52% Actions
GOLDMAN SACHS GROUP INC $5 426 210 3 229 887 1,51% Actions
CITADEL ADVISORS LLC $4 781 117 2 845 903 1,33% Actions
VANGUARD PORTFOLIO MANAGEMENT LLC $4 488 819 2 671 916 1,25% Actions
CHARLES SCHWAB INVESTMENT MANAGEMENT INC $4 455 861 2 652 298 1,24% Actions
NORTHERN TRUST CORP $3 952 681 2 352 786 1,10% Actions
VANGUARD FIDUCIARY TRUST CO $3 675 213 2 187 627 1,02% Actions
SUSQUEHANNA INTERNATIONAL GROUP, LLP $3 577 162 2 129 263 0,99% Actions
Longaeva Partners L.P. $3 558 628 2 118 231 0,99% Actions
IQ EQ FUND MANAGEMENT (IRELAND) Ltd $2 846 837 1 694 546 0,79% Actions
Birchview Capital, LP $2 268 000 1 350 000 0,63% Actions
BANK OF AMERICA CORP /DE/ $2 264 860 1 348 131 0,63% Actions
Invesco Ltd. $2 179 114 1 297 091 0,61% Actions
AQR CAPITAL MANAGEMENT LLC $2 178 430 1 296 684 0,61% Actions
Nuveen, LLC $1 718 830 1 023 113 0,48% Actions
RENAISSANCE TECHNOLOGIES LLC $1 623 216 966 200 0,45% Actions
BOURNE LENT ASSET MANAGEMENT INC $1 584 332 943 055 0,44% Actions
TWO SIGMA ADVISERS, LP $1 547 425 827 500 0,43% Actions
HHLR ADVISORS, LTD. $1 543 739 918 892 0,43% Actions
UBS Group AG $1 500 475 893 140 0,42% Actions
Universal- Beteiligungs- und Servicegesellschaft mbH $1 358 616 808 700 0,38% Actions
Bank of New York Mellon Corp $1 289 512 767 567 0,36% Actions
DIMENSIONAL FUND ADVISORS LP $1 277 135 759 783 0,35% Actions
Casdin Capital, LLC $1 215 929 723 767 0,34% Actions
TUDOR INVESTMENT CORP ET AL $1 150 308 684 707 0,32% Actions
XTX Topco Ltd $1 073 322 638 882 0,30% Actions
Numerai GP LLC $1 044 068 621 469 0,29% Actions
CARRET ASSET MANAGEMENT, LLC $1 008 235 600 140 0,28% Actions
Man Group plc $1 003 521 597 334 0,28% Actions
Russell Investments Group, Ltd. $1 002 694 596 843 0,28% Actions
Balyasny Asset Management L.P. $948 090 564 339 0,26% Actions
PEAK6 LLC $933 327 555 552 0,26% Actions
Vestmark Advisory Solutions, Inc. $803 384 478 205 0,22% Actions
MORGAN STANLEY $802 664 477 776 0,22% Actions
ArrowMark Colorado Holdings LLC $786 882 468 382 0,22% Actions
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. $741 954 441 639 0,21% Actions
SUSQUEHANNA INTERNATIONAL GROUP, LLP $673 008 400 600 0,19% Option de vente

Afficher les 244 détenteurs institutionnels →

Activistes et détenteurs de 5%+ 1 participation

18

Investisseurs ayant déposé un Schedule 13D auprès de la SEC — détention effective supérieure à 5% avec l'intention d'influencer l'émetteur (participations activistes, campagnes pour le conseil d'administration, fusions-acquisitions). Chaque ligne montre le dernier état connu de la position du déposant.

Déclarant Déposé Participation Statut Objectif Dépôt
Magnetar Financial LLC, Magnetar Capital Partners LP, Supernova Management LLC, Alec N. Litowitz ×3 dépôts 29 août 2019 · Dépôt initial · SEC

Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.

Initiés de la société 30 initiés · 6 dirigeants · 11 administrateurs

19
Dirigeant Rôle Dernière activité Actions détenues Achats 12m Ventes 12m Net 12m
Mark Van Oene President & CEO 17 août 2026 S 2 705 853 0 4 $-335 122
Susan K Barnes EVP, CFO and PAO 19 février 2020 S 874 812 0 0 $0
James Michael Phillips SVP, Research & Development 24 mars 2020 S 249 220 0 0 $0
Kevin P Corcoran SVP, Market Development 24 novembre 2017 M 158 174 0 0 $0
Michael Glynn Chief Commercial Officer 15 février 2012 A · 0 0 $0
Stephen W Turner VP & Chief Technology Officer 11 juillet 2011 J 1 093 063 0 0 $0
Christopher Gibson Administrateur 3 juin 2026 A 111 386 0 0 $0
Hannah Valantine Administrateur 3 juin 2026 A 22 821 0 0 $0
William W. Ericson Administrateur 3 juin 2026 A 41 616 0 0 $0
Christopher M Smith Administrateur 3 juin 2026 A 54 099 0 0 $0
Marshall Mohr Administrateur 3 juin 2026 A 132 821 0 0 $0
Randall S Livingston Administrateur 3 juin 2026 A 22 821 0 0 $0
Kathy Ordonez Administrateur 3 juin 2026 A 403 037 0 0 $0
John F Milligan Administrateur 3 juin 2026 A 132 821 0 0 $0
David B. Singer Administrateur 13 juin 2012 A · 0 0 $0
Susan E Siegel Administrateur 13 juin 2012 A 65 000 0 0 $0
Hugh C Martin Administrateur 3 février 2012 M 342 458 0 0 $0
James R Gibson II · 1 avril 2026 S 1 245 663 0 1 $-120 813
Michele Farmer · 3 mars 2026 S 305 948 0 3 $-84 510
Christian O Henry · 3 mars 2026 S 3 581 813 0 3 $-772 728
Lucy Shapiro · 4 juin 2025 A 22 821 0 0 $0
Susan G. Kim · 30 septembre 2024 S 695 654 0 0 $0
Jeff Eidel · 19 août 2024 S 869 730 0 0 $0
David W Meline · 18 juin 2024 A 57 116 0 0 $0
David Botstein · 24 mai 2023 A 0 0 0 $0
Peter Fromen · 2 mars 2022 A 190 280 0 0 $0
Michael Hunkapiller · 26 février 2021 M 848 405 0 0 $0
Eric Schaefer · 22 février 2021 S 88 474 0 0 $0
BYERS BROOK H · 17 mai 2016 A 110 504 0 0 $0
Brian B Dow · 2 mars 2015 P 18 119 0 0 $0

Initiés issus des déclarations SEC Form 3/4/5 ; net = uniquement P/S de marché

Détention d'ETF Détenu par 21 ETFs

20

Le poids reflète uniquement les participations directes en actions (N-PORT) ; les fonds à effet de levier ou basés sur des dérivés peuvent détenir une exposition supplémentaire aux swaps non indiquée.

Fonds Poids Unités Au Source
ARKG · ARK ETF Trust 0,96% 10 630 263 NS 31 juillet 2026 N-PORT
QQQS · Invesco Exchange-Traded Fund Trust … 0,91% 88 548 SH 1 octobre 2026 Quotidien
IDNA · iShares Trust 0,35% 711 655 SH 11 septembre 2026 Quotidien
ARKK · ARK ETF Trust 0,32% 12 810 378 NS 31 juillet 2026 N-PORT
PRFZ · Invesco Exchange-Traded Fund Trust 0,09% 1 001 721 SH 1 octobre 2026 Quotidien
IBBQ · Invesco Exchange-Traded Fund Trust … 0,05% 21 993 SH 1 octobre 2026 Quotidien
VTWG · VANGUARD SCOTTSDALE FUNDS 0,03% 280 941 SH 19 août 2026 Quotidien
IBB · iShares Trust 0,03% 2 192 352 SH 11 septembre 2026 Quotidien
IWO · iShares Trust 0,02% 2 473 318 SH 11 septembre 2026 Quotidien
RSSL · Global X Funds 0,01% 134 834 NS 31 juillet 2026 N-PORT
IWM · iShares Trust 0,01% 7 217 251 SH 11 septembre 2026 Quotidien
VXF · VANGUARD INDEX FUNDS 0,01% 3 579 782 SH 19 août 2026 Quotidien
VTWO · VANGUARD SCOTTSDALE FUNDS 0,01% 1 624 029 SH 19 août 2026 Quotidien
VHT · VANGUARD WORLD FUND 0,01% 727 094 SH 19 août 2026 Quotidien
ITOT · iShares Trust 0,00% 431 328 SH 11 septembre 2026 Quotidien
IWV · iShares Trust 0,00% 69 680 SH 9 septembre 2026 Quotidien
VTI · VANGUARD INDEX FUNDS 0,00% 9 535 565 SH 19 août 2026 Quotidien
VTWV · VANGUARD SCOTTSDALE FUNDS 0,00% 17 047 SH 19 août 2026 Quotidien
VTHR · VANGUARD SCOTTSDALE FUNDS 0,00% 22 805 SH 19 août 2026 Quotidien
DFAC · Dimensional ETF Trust 0,00% 8 144 NS 31 juillet 2026 N-PORT
IWN · iShares Trust · 207 024 SH 11 septembre 2026 Quotidien

PACB Consensus des analystes Opinions des analystes haussières et baissières, objectif de cours à 12 mois, potentiel de hausse

21
notation · 14 analystes ACHAT
Objectif médian $2.00 -21,3%
4 28,6% Achat fort
5 35,7% Achat
4 28,6% Conserver
1 7,1% Vente
0 0,0% Vente forte

Objectif de cours à 12 mois

7 analystes · 2026-10-02

Objectif moyen $2.16 -15,1%

Maintenant Prix actuel $2.54
Bas$1.25 Moyenne$2.16 Haut$3.00

Comparaison des pairs (sous-secteur GICS) Indicateurs clés par rapport aux pairs du secteur

22

Base F.A., prix à la clôture de la dernière fin d'exercice de chaque société.

Ticker Capitalisation Boursière P/E Revenus Année/Année Marge Nette ROE Marge Brute
PACB $565M -1.0 3.9% -341.5% -1634.9% 28.6%
BLFS · -241.8 28.9% · · ·
PSNL $816M -8.7 -17.7% -116.7% -36.0% ·
AZTA $1.32B -23.5 3.5% -9.4% -3.3% 45.5%
CYRX $479M 6.9 12.4% 44.4% 15.3% 47.1%
DNA $484M -1.5 -25.1% -183.8% -55.8% ·
CTKB $649M 505.0 0.52% -33.0% -18.5% 51.8%
MLAB $489M 73.1 3.4% 2.7% 3.7% 63.5%
OABI · · · · · ·
TKNO $204M -11.9 7.3% -42.6% -23.8% 33.2%
QSI · · · · · ·

Mes métriques Votre watchlist personnelle — lignes sélectionnées de Fondamentaux Complets

26

Choisissez les indicateurs qui vous importent — cliquez sur le + à côté de n'importe quelle ligne dans les Fondamentaux complets ci-dessus.

Votre sélection est enregistrée et vous suit sur tous les tickers.

Source : Dépôt SEC 10-Q le Aoû 6, 2026